Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2016-002105-18-FI
EUCTR2016-002105-18-FIActive, not recruitingPhase 1

aboratory measurement of direct oral anticoagulants on patients with atrial fibrillation - Laboratory measurement of anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban.

Helsinki City Hospital Haartman0 sitesStarted: October 19, 2016Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Patients who present with atrial fibrillation.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 50
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 100

Exclusion Criteria

  • •Valvular atrial fibrillation (mechanical heart valve or mitral stenosis), active malignancy, contraindication to anticoagulation (eg. severe bleeding tendency), severe thrombophilia (eg. lupus anticoagulant).

Investigators

Sponsor
Helsinki City Hospital Haartman

Similar Trials

Completed
Not Applicable
Detection of direct oral anticoagulants with ClotProD68Other coagulation defects
DRKS00015302Klinik für Anästhesiologie, Klinikum der Universität München, LMU München80
Active, not recruiting
Phase 1
Monitoring the effect of blood thinners during percutaneous coronary interventioAnticoagulation during percutaneous coronary intervention
EUCTR2020-005298-29-NLSt. Antonius Hospital120
Recruiting
Phase 4
Monitoring the effect of oral anticoagulants during cardiac catheterisatiocoronary artery diseasepercutaneous coronary intervention10011082
NL-OMON50931Sint Antonius Ziekenhuis120
Recruiting
Phase 3
A randomized controlled, multicenter trial investigating management of Direct Oral anticoagulant (DOACs) for colorectal polypectomyColorectal polyp
JPRN-UMIN000039418Osaka International Cancer Institute400
Recruiting
Phase 4
Pharmacologic profile of direct oral anticoagulants in patients receiving Rituximab-CHOP chemotherapyewly diagnosed non-Hodgkin lymphoma,diffuse large B-cell lymphoma subtype,and who are planned to be treat with R-CHOP chemotherapy regimen
TCTR20200824001Faculty of medicine Chiang Mai university26